We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Swiss drugmaker Novartis has announced plans to build an integrated biomedical R&D center in the Zhangjiang Hi-Tech Park in Shanghai, China, that will become an integral part of the company's global research and development network.
The board of The Global Fund to Fight AIDS, Tuberculosis and Malaria has approved $604 million in new grants to fight the three diseases, bringing the fund's total portfolio of grants to $6.4 billion in 135 countries.
An additional 3.8 million people in the U.S. without prescription drug coverage will be eligible for free drugs from AstraZeneca thanks to an expansion in the company's Patient Assistance Program.
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has posted a notice on its website of a Class 2 drug alert because Lexon is recalling a batch of Aricept (donepezil hydrochloride).
BioMarin Pharmaceutical has announced that Japan's Ministry of Health, Labor and Welfare has granted marketing authorization for Aldurazyme (laronidase), the first specific treatment approved in Japan for patients with the genetic disease mucopolysaccharidosis I (MPS I).
A new anti-malaria drug, made by Chinese drugmaker Kunming Pharmaceutical, has been introduced in Uganda, reports the Kampala, Uganda-based New Vision.
Swedish drugmaker Gendux and Introgen Therapeutics announced they have reached agreement with the European Medicines Agency (EMEA) to apply for Advexin p53 therapy marketing approval under the EMEA's exceptional circumstances provisions.
New Zealand's Pharmaceutical Management Agency (PHARMAC) has announced that a new once-a-day medicine to treat HIV is now part of a package of available HIV treatments.